AstraZeneca Enhertu breast cancer drug is recommended for EU approval
June 27, 2022 at 03:11 AM EDT
The decision was based on trial results showing that Enhertu cut the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.
